{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:46:13Z","timestamp":1781541973555,"version":"3.54.5"},"reference-count":40,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>In factor VIII (FVIII) prophylaxis for haemophilia A, cost comparisons have used price per international unit (IU) based on the once reasonable assumption of equivalent outcome per IU. Now, with several extended half\u2010life (EHL) products available, new outcome\u2010oriented ways to compare products are needed. Area under the curve (AUC) quantifies FVIII levels over time after infusion providing comparable data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To develop a decision analytical model for making indirect comparisons of FVIII replacement products based on AUC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A literature search identified 11 crossover studies with relevant pharmacokinetic data. A common comparator FVIII level curve was calculated using pooled data from selected studies. Absolute curves for other products were estimated based on relative differences to the common comparator (% difference vs the anchor). Three scenarios were investigated: (1) Kogenate<jats:sup>\u00ae<\/jats:sup> versus Kovaltry<jats:sup>\u00ae<\/jats:sup> and Jivi<jats:sup>\u00ae<\/jats:sup>; (2) Advate<jats:sup>\u00ae<\/jats:sup> versus Elocta<jats:sup>\u00ae<\/jats:sup>, NovoEight<jats:sup>\u00ae<\/jats:sup>, Kovaltry, Adynovate<jats:sup>\u00ae<\/jats:sup>, Afstyla<jats:sup>\u00ae<\/jats:sup>, and ReFacto<jats:sup>\u00ae<\/jats:sup>; and (3) Jivi versus Elocta, Adynovate, and Kogenate. Sensitivity analyses investigated effects of assay type and dose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In scenario 1, Jivi (+50%) and Kovaltry (+14%) showed larger AUCs versus Kogenate. In scenario 2, EHL products, Elocta and Adynovate, had the largest AUC (+64% and +58%, respectively) versus Advate. Compared with all other products in scenario 3, Jivi had the largest AUC by +13%\u201328%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This analysis concludes that EHL products differ in relative AUC, have a larger AUC compared with standard half\u2010life, and thus, different FVIII levels over time after infusion. This model may aid decision makers in the absence of head\u2010to\u2010head data.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.14691","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T15:53:17Z","timestamp":1669737197000},"page":"145-155","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A"],"prefix":"10.1111","volume":"29","author":[{"given":"Sofie","family":"Persson","sequence":"first","affiliation":[{"name":"Swedish Institute for Health Economics  Lund Sweden"},{"name":"Department of Clinical Sciences Lund University  Lund Malm\u00f6 Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Berndt","sequence":"additional","affiliation":[{"name":"Bayer AB  Solna Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Engstrand","sequence":"additional","affiliation":[{"name":"Bayer A\/S  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annegret","family":"Trinczek","sequence":"additional","affiliation":[{"name":"Bayer AB  Solna Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina Steen","family":"Carlsson","sequence":"additional","affiliation":[{"name":"Swedish Institute for Health Economics  Lund Sweden"},{"name":"Department of Clinical Sciences Lund University  Lund Malm\u00f6 Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Berntorp","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine Lund University  Lund Malm\u00f6 Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61139-2"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.27.3.316"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0660-y"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-016-0785-2"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-470898"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2015.1016228"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.01.001"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12887"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.04.1705"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.05.005"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100852"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12905"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720966888"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12761"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02370.x"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13215"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02909.x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16704"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00049-8"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12150"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12916"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13867"},{"key":"e_1_2_9_25_1","unstructured":"RohatgiA. WebPlotDigitizer: web based tool to extract numerical data from plotts. 4.4 ed 2021."},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12691"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12506"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-529974"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-382846"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12816"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0492-2"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-630897"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12985"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01420.x"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03747-2"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04280-3"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1721484"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12672"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13643"},{"issue":"2","key":"e_1_2_9_40_1","article-title":"Predicted FVIII consumption of BAY 94\u20139027 compared with standard\u2010 and extended\u2010half\u2010life FVIII products in patients with severe hemophilia A [abstract]","volume":"5","author":"Solms A SA","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13935"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14691","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.14691","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14691","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T22:16:17Z","timestamp":1692310577000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1111\/hae.14691"],"URL":"https:\/\/doi.org\/10.1111\/hae.14691","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"assertion":[{"value":"2022-03-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}